Menu
Recruiting NCT03911700

Prophylactic Reinforcement of Ventral Abdominal Incisions Trial

No phase Interventional Open Midline Laparotomy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Phasix™ Mesh.
Who it may be relevant to
Registry conditions: Open Midline Laparotomy. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States, Austria, Belgium, France, Germany
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Prospective, Multi-Center, Open-Label, Randomized, Controlled Trial of Phasix™ Mesh to Prevent Incisional Hernia Subsequent to Open Midline Laparotomy

Overview

This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.

Detailed description

Subjects will be randomized (1:1) to one of the two treatment groups in the operating room after fascial closure.

Interventions

  • Device Phasix™ Mesh
    Phasix™ Mesh is a resorbable mesh prepared from Poly-4-hydroxybutyrate (P4HB).

Primary outcome measures

  • Rate of Incisional Hernia [Time frame: 24-Months]
Secondary outcome measures (7)
  • Rate of Incisional Hernia [Time frame: 60-Months]
  • Rate of Device-related Adverse Events (AEs) [Time frame: 60-Months]
  • Length of surgical procedure in minutes [Time frame: Study Day 0]
  • Length of time for wound closure in minutes [Time frame: Study Day 0]
  • Length of hospital stay in days [Time frame: Through hospital stay, typically 3 days]
  • Quality of Life: Optum Short Form Survey 12 Item Version 2 (SF-12v2®) [Time frame: 60-Months]
  • Quality of Life: EuroQoL-5 Dimensions-3 Level (EQ-5D-3L©) [Time frame: 60-months]

Eligibility criteria

Inclusion criteria

  • Must be ≥ 18 years of age
  • Elective, open midline laparotomy ≥ 5 cm
  • Willing and able to provide written informed consent
  • Hernia risk equal to moderate or greater

Exclusion criteria

  • Previous hernia repair
  • Emergent surgery
  • Creation of skin flaps is preplanned
  • Preplanned 2nd surgery
  • Active skin pathology
  • Life expectancy less than 24 months
  • Pregnant or planning to become pregnant
  • Receiving a medication/medical condition that may adversely affect wound healing
  • ASA Class > IV
  • Enrolled in another clinical trial
  • Site personnel directly involved with this trial
  • Any condition that would preclude the use of the device or the subject form completing the follow-up requirements
  • Known or suspected allergy to tetracycline hydrochloride or kanamycin sulfate
  • Two separate incisions are created
  • Prior onlay mesh
  • Surgeon is unable to fully close the fascia
  • The surgery requires more than a single piece of mesh
  • Contraindication to placement of mesh
  • CDC Class IV/Active Infection
  • Breastfeeding

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Prevention

Study locations

United States · 31 centers
  • Dignity Health — Phoenix
  • Keck Medical Center of USC — Los Angeles
  • University of California San Francisco — San Francisco
  • Hartford Hospital — Hartford
  • St. Francis Hospital and Medical Center — Hartford
  • Emory University — Atlanta
  • OSF Saint Francis Medical Center — Peoria
  • Indiana University — Indianapolis
  • … and 23 more centers
France · 7 centers
  • CHU de Dijon Bourgogne — Dijon
  • Centre Hospitalier Universitaire de Lille — Lille
  • Centre Hospitalier Universitaire de Lille — Lille
  • Hôpital Paris St Joseph — Paris
  • Hôpital Lyon Sud — Pierre-Bénite
  • CHU Reims — Reims
  • Hopitaux Universitaires de Strasbourg — Strasbourg
Germany · 5 centers
  • Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Gyneocology — Berlin
  • Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Surgery — Berlin
  • Asklepios Klinik Barmbek — Hamburg
  • Universitätsklinikum Heidelberg — Heidelberg
  • Bundeswehrzentralkrankenhaus Koblenz — Koblenz
Austria · 1 center
  • Krankenhaus der Barmherzigen Brüder Graz — Graz
Belgium · 1 center
  • Universitair Ziekenhuis Gent — Ghent

Identifiers

NCT: NCT03911700 · DVL-HE-018

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗